DOMAIN Therapeutics

🚀We’re beyond excited to share that our company has been nominated for the prestigious Prix Galien USA in the “Best Startup” category!🏆 This incredible honor reflects our unwavering commitment to #innovation and excellence in developing groundbreaking treatments that target GPCR-mediated immunosuppression, aiming to overcome the limitations of current therapies. At Domain, we are at the forefront of two transformative fields: G Protein-Coupled Receptors (GPCRs) and the immune system. GPCRs are pivotal in #drugdiscovery, accounting for 30% of all marketed drugs, yet their full potential remains untapped. The intricacies of immunosuppression and immunoresistance within the Tumor Micro-Environment significantly impact treatment outcomes, often leading to therapeutic failure for some cancer patients. By integrating GPCRs and immune system, we are pioneering a new frontier in #immunooncology, redefining therapeutic possibilities for cancer patients with high unmet needs. This synergy, still largely unexplored, holds immense promise, offering vast opportunities for #drugdevelopment in #cancertreatment. Leveraging our cutting-edge target (GPCR) identification platform and precision science that builds upon two decades of GPCR expertise, we deliver a unique pipeline of GPCR-targeting drug candidates with competitive properties. We’re deeply honored to be recognized by The Galien Foundation and Business France North America. 🗓️Mark your calendars for the Prix Galien USA Forum on the 7th of November, where winners will be announced! Our journey is powered by visionary international venture capital firms, including 3B Future Health Fund I & II, Seventure Partners, Schroders Capital, Omnes, Turenne Groupe, Theodorus Investment Funds, Panacea Venture, Viva BioInnovator, CTI Life Sciences Fund and adMare BioInnovations. Their belief in our mission drives us forward, and we are immensely grateful for their support. Together, we’re revolutionizing precision-enabled immunotherapies, making them accessible to patients worldwide! 🌍✨

Sarcoma is not only a rare tumor, it often goes unnoticed until it’s too late. This is the harsh reality for sarcoma patients. They deserve more than just conventional treatments. They deserve breakthroughs! Sarcoma Awareness Month is a powerful reminder of the immense challenges faced by those living with this rare cancer. Late or incorrect diagnoses and limited treatment options significantly impact their lives. These patients’ stories of resilience and courage drive us to push the boundaries of science and medicine to create effective treatments and provide hope! At Domain, we are proud to be part of the groundbreaking RHU CONDOR program, a lifeline for Soft Tissue Sarcoma (STS) patients. This consortium unites multidisciplinary experts, combining #precisionmedicine and #immunotherapy. Led by Prof. Italiano Antoine, a valuable member of our Scientific Advisory Board, we’re pioneering a unique strategy for STS, providing new possibilities for patients with poor prognoses or ineffective treatment options. How are we making a difference? By leveraging over 20 years of GPCR expertise and advanced knowledge of the tumor microenvironment, precision tools and biomarkers, we are paving the way for more effective and safer treatments for sarcoma patients. Our lead clinical candidate in the CONDOR project, DT-9081, an EP4R antagonist, is set to move to Phase II in early 2025. This game-changing therapy has the potential to improve immune responses to sarcoma and address resistance mechanisms to current therapies. Learn more about sarcoma in the illustration below. Let’s stand with those affected by sarcoma. Share this post to amplify awareness and support the fight against this challenging disease. Together, we can make a difference. #immunooncology #CancerResearch #drugdevelopment

As we approach the 2-year anniversary of our #bestinclass proprietary choir, Domain Therap N Sing, we’re excited to share a heartwarming summer story that recently unfolded. Our talented choir members from various departments, united by their love for music, came together once again to spread joy beyond Domain’s corporate walls. 🌟 Twice a year, Domain Therap N Sing has the honor, thanks to the remarkable volunteer association Les Blouses Roses, to perform at the retirement home Ehpad Abrapa Illkirch. This summer’s concert was a beautiful blend of voices, stirring emotions and creating a shared experience that transcends words and touches hearts.   🌿 Beyond its artistic beauty, music has a profound impact on well-being. The soothing notes and uplifting melodies gently ease stress and, at time, even physical discomfort. Through the universal language of music, we bridge generational gaps, fostering unity and mutual understanding. This moment of sharing was further enriched by a convivial exchange over refreshments, weaving lasting bonds that bring joy to both young and elderly. We extend our heartfelt gratitude to Angélique Q., the passionate president of Les Blouses Roses Strasbourg, and Manuela Rovira, our devoted singing teacher whose guidance has nurtured our choir’s growth. We also thank our management for providing us with this wonderful opportunity!   Music stimulates creativity and focus, much like the precision science that is at the heart of Domain. Together, we harmonize science and art! Let’s keep the rhythm alive, spreading the summer vibe and making a difference, one note at a time. ❤️ 🎶 #PatientCentricity #TransformingLives #innovation

🌟Our team has secured 8th place out of 246 participants in our category in the 15th anniversary edition of the "Bike to Work" challenge (Au boulot à vélo)! That’s a leap forward from last year, getting closer to the top finalists! Way to go TEAM 👏 🏆 We are extremely proud to share with you our remarkable results 😊 -we’ve cycled an impressive 6,691.83 kilometers. Imagine cycling from Paris to Chicago, IL that’s the distance we’ve covered! 🌎🌱 -by swapping our cars for bikes, we’ve collectively reduced our carbon footprint by approximately 1,500 kg of CO2. That’s equivalent to the CO2 absorbed by 75 trees in a year or powering 29387 online searches. 🌳 🚲💚Many of our colleagues have embraced the joy of cycling to work or use public transport all year around. This challenge has not only highlighted our #teamspirit and the environmental benefits of our daily commutes but also underscored the health-conscious culture that thrives within our company. At Domain Therapeutics, our commitment to sustainability goes beyond our cutting-edge innovation in GPCR-targeting therapies. It’s reflected in our everyday actions and choices, embodying our mission to make a real difference for our local and global communities. 🌏 We take pride in our #softmobility policy, which promotes eco-friendly transportation options and facilitates sustainable commuting for our team. Choosing to cycle to work is not just practical and economical, but it’s also a fun, energizing and eco-responsible alternative that can make a real impact on our planet. A big thank you to everyone who participated and supported this initiative!  Check out the video capturing our enthusiasm, cycling and summertime vibes! Let's keep this momentum going, both on and off the bike, as we enjoy the outdoors and stride towards a greener, healthier, and more sustainable future together! #sustainabilitymatters #teamspirit #challengeaccepted Ville et Eurométropole de Strasbourg

A week of discovery and progress at Domain! Last week our company headquarters were buzzed with excitement as we hosted our Science Day, and had the honor of welcoming our Board of Directors. These successful events showcased our progress and celebrated the collective efforts of our incredible team to bring solutions to patients facing therapeutic failure in the clinic. With over two decades of solid expertise in GPCR #drugdiscovery, Domain is pioneering GPCR therapeutic target identification and cutting-edge science to harness the power of the immune system and deliver therapeutic solutions to patients in the clinic. We are committed to addressing complex diseases by combining patient-centricity and #innovation, driving change and providing the unprecedented access to precision-enabled immunotherapies. Our Science Day was a vibrant platform to present our precision research, the depth of our know-how and experience of our Domain' team to advance our robust pipeline of disruptive assets. GPCRs, instrumental in drug discovery and accounting for 30% of all marketed drugs, hold immense therapeutic potential. Yet, their full potential remains largely untapped. At Domain, we are on a mission to change that. Our innovative approach focuses on uncovering new and even intractable GPCR targets, transforming GPCR drug discovery into life-changing medicines for patients worldwide. Last week’s events were a great illustration of the scientific productivity and research quality at Domain, reflecting the dynamic atmosphere within our research environment. It was incredibly inspiring to see how aligned our investors are with our goals. Their unwavering support, strategic insights experience and proven track record across various sectors are propelling our development forward. As Domain continues to play a pivotal role in within the biotech and pharmaceutical industry, the collective expertise of our Board of Directors and our highly experienced team fuels our determination to drive innovation and excellence in our therapeutics solution offerings. We extend our heartfelt thanks to Roberto De Ponti, Laurence Rulleau,PhD, Sylvie Ryckebusch, James Huang, Frederic Lemaitre Auger and Erwin Boos for their invaluable contributions and to everyone else who made our recent events a success! Together, we are unlocking GPCR potential into tangible achievements for a better tomorrow. #drugdevelopment #precisionmedicine #immunotherapy

🚴♂️ 🚴♀️ This June, team Domain is once again rising to the challenge of Bike to work (Au boulot à vélo)! Every kilometer cycled, whether commuting, attending meetings, business trips, or even working from home, contributes to our collective goal. It’s simple: we’re swapping four wheels for two! 🚴♀️ 🚴♂️ What if your daily commute could boost your health, team spirit and save the planet? 😉  👉 #HealthAndWellness. Cycling to work keeps us fit, energized and ready to tackle the day!  👉 #EnvironmentalImpact. By choosing bikes over cars, we are reducing pollution and easing urban traffic!  👉 #TeamSpirit. It isn’t just about the distance, it’s about the collective effort!  👉 #SustainabilityMatters. Cycling to work is one of the many ways we’re committed to protecting the environment, a commitment that is deeply embedded into our company’s DNA. 💚 Last year, we pedaled nearly 10,000 kilometers, securing the 9th spot out of 243 teams. That’s 2.53 tons of CO2 emissions avoided, equivalent to a trip from Paris to La Réunion! This year, we’re aiming to go even further. 💪 🙏 A big thank you to everyone representing our #biotech in this sporting and collaborative challenge. And guess what? Many of us at Domain don’t limit ourselves to just one month, we enjoy cycling year-round! So grab your helmets, oil those chains, and together, let’s pedal toward a healthier and greener future! 🌍 🌱 #sustainableliving #ChallengeAccepted

We’re thrilled to announce the publication of three international Patent Cooperation Treaty (PCT) patent applications that cover our groundbreaking series of Treg-depleting anti-CCR8 monoclonal antibodies, including our lead candidate DT-7012. By securing intellectual property rights across diverse markets, these new patents expand the geographic protection of our game-changing Treg depleting ADCC/ADCP CCR8 antibodies, underscoring their broad therapeutic application. And the timing couldn’t be better, our accelerated R&D efforts in #immunooncology align seamlessly with this PCT publication. The CCR8 GPCR target is specifically expressed by tumor infiltrating Tregs, key immunosuppressive cells within the tumor microenvironment (TME). Their presence compromises the efficacy of existing immunotherapies. Blocking CCR8 is a highly strategic approach in immuno-oncology, increasing clinical success rates in non-responding patients! DT-7012 is a novel anti-CCR8 monoclonal antibody that depletes tumor-infiltrated Tregs within the TME, leveraging ADCC/ADCP mechanisms. Compared to other clinical-stage anti-CCR8 antibodies, DT-7012 has a proven best-in-class potential in activating antitumor immunity for cancer patients unresponsive to other treatments and paving the way for the development of effective GPCR-targeting immunotherapies. As we forge ahead, pushing the boundaries of innovation in cancer treatment, we invite you to follow our progress. We’re committed to revolutionizing GPCR #drugdevelopment and broadening therapeutic options to improve clinical outcomes for cancer patients. #precisionmedicine #immunotherapy #techinnovation #GameChanger

Did you know that some skin conditions could be more than what they seem? This May, as we observe Skin #CancerAwareness Month, let’s shed light on rare cancers that affect the skin, such as cutaneous T-cell lymphoma (CTCL), which may be mistaken for noncancerous conditions, such as eczema and psoriasis, leading to delayed diagnosis and treatment. CTCL affects about one in 100,000 adults worldwide annually, nearly tripling in last 30 years. With a median survival rate of less than 5 years for advanced stages and no established standard-of-care, patients’ lives are profoundly impacted. That is why at Domain we are actively working to understand the underlying factors guiding disease progression. We’re exploring the tumor microenvironment in CTCL and the predictive biomarkers available for clinical use. With the support of ANR, the French National Research Agency as a part of #France2030 investment plan, we are part of the Hospital-University Research in Health (RHU) SPRINT aiming to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care. This consortium is at the beginning of the collaborative journey with world-class academics and highly innovative companies, including @Université Paris Cité Hospices Civils de Lyon - HCL Greater Paris University Hospitals - AP-HP CHU de Bordeaux INSERM TheraPanacea, and more. United in our commitment, we are pushing the boundaries of therapeutic innovation, bringing new hope to CTCL patients. We’re proud to contribute to this project with our innovative precision research and our novel drug candidate, DT-7012, a Treg depleting anti-CCR8 monoclonal antibody. This best-in-class candidate holds an immense potential to overcome Treg-mediated resistance to #immunotherapy, reshape the tumor microenvironment, and unlock the immune system’s cancer fighting abilities. #precisionmedicine #drugdiscovery #cancerresearch The Skin Cancer Foundation

As we mark the 250th year anniversary of the first randomised trial, it is a timely moment to reflect on the significant progress in #clinicalresearch and its monumental impact on human health. In the field of cancer treatment, the research journey has seen many successful therapeutic strategies and substantial innovation in #clinicaltrials and regulatory frameworks. Yet, the quest for a cure continues. This highlights the critical need for trials that are not only patient-centric, but also strategically planned, and executed with precision. Due to the heterogenous nature of cancer, its mechanisms of resistance remain a big challenge. At Domain, we’re dedicated to understanding these complexities to determine an optimal therapeutic strategy. We are at the forefront of developing novel treatments that target G Protein Coupled Receptor (GPCR) mediated immunosuppression. GPCRs have long been overlooked in cancer therapy, but their significance is now undeniable to advance innovation the field. They play a pivotal role in shaping immune responses against tumors and their modulation holds an immense promise to redefine cancer treatment. We apply thoughtful design to our trials, combining strategic GPCR therapeutic targets with comprehensive biomarkers, carefully selected patient sub-populations and robust data management to enhance trial efficiency and success rates aiming to turn non-responder cancer patients into responders. Our lead clinical candidate, DT-9081, the EP4R antagonist is moving towards Phase II trials and our groundbreaking Treg-depleting anti-CCR8 monoclonal antibody candidate, DT-7012, is expected to start Phase I trials in mid-2025. This progress would not be possible without the amazing dedication of our team, collaborations, innovation, and our shared passion for advancing therapeutic progress in cancer therapy. On the clinical trials day, and every day, we salute patients, clinicians, investigators and researchers whose unwavering efforts are revolutionising the cancer treatment landscape and paving a way to a healthier future for millions of people across the globe. Join us in this celebration of progress and hope. Together, let’s make a difference! #drugdevelopment #immunooncology #precisionmedicine

It was an absolute pleasure to welcome bioengineering students from Clemson University in South Carolina, United States, along with their respected faculty leader Dr. Heather Dunn! At Domain, we believe in the power of knowledge transfer. Our engagement was not just about the fascinating domains of #immunooncology, #cancerresearch and innovative #drugdevelopment techniques. It was about sparking a dialogue that bridges academia and industry, nurturing the next generation of biotech leaders. In line with this belief, our Vice President of Business Development and Communication Marjorie Sidhoum initiated the presentation introducing Domain Therapeutics as the leading GPCR immuno-oncology company, thereby setting the stage for a rich exchange of ideas and insights. Why focus on GPCRs in immuno-oncology to defeat cancer? Our Chief Scientific Officer Stephan Schann led an insightful session on this largest family of human receptors which play a pivotal role in modulating the immune system, tumor biology and the tumor microenvironment. The students learned that unlocking GPCR-mediated immunosuppression opens doors to groundbreaking therapeutic solutions, maximizing benefits to cancer patients worldwide. The hands-on experience continued with our Head of Clinical Operations Claire Jouffroy-Zeller who delved into DT-9081, a small molecule candidate targeting the EP4 receptor. By showcasing how a differentiated drug development process maximizes cancer treatment success rates, we provided the students with practical insights. Our chemistry and translational departments took center stage, offering the students an opportunity to discover benchwork side of our drug discovery process in our laboratories and interact with our passionate scientists Christelle Doebelin and María Dolores García Fernández. They glimpsed firsthand the precision-enabled science driving our innovation. The students’ curiosity sparked a flurry of interesting questions, reaffirming their passion for #biothechnology, healthcare and research. We are proud to share our innovative science to create a transformative impact that drives advancements in the industry. We extend our heartfelt thanks to the Cepa Foundation for facilitating this initiative and recognize our Domain team whose dedication and expertise are cornerstones of our success! To the students, we wish you a summer full of discovery and a future bright with innovation and success! #precisionmedicine #futureofhealthcare